Kyleena 19.5 MG systems
Ended Awarded
- Contract number
- SPE2DB26FL0D3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,985
Award facts
- Contract value 100% obligated
- $30,984.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $30,984.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Kyleena 19.5 mg contraceptive systems. The delivery order, issued on October 31, 2025, with an ultimate completion date of November 24, 2025, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying diverse pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V contract, designated SPE2DR and valued at approximately $500 million, was awarded on November 13, 2025, with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The contract authorizes the Defense Logistics Agency to issue delivery orders for a comprehensive range of pharmaceuticals including branded and generic prescription medications, biologics, vaccines, and medical consumables to support recurring medical supply requirements of military healthcare operations globally. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated substantial performance capability across multiple therapeutic categories and product lines through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DB26FL0D3?
SPE2DB26FL0D3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 31, 2025.
How much is contract SPE2DB26FL0D3 worth?
The government has obligated $30,985 on SPE2DB26FL0D3.
Is contract SPE2DB26FL0D3 an order under another contract?
Yes. SPE2DB26FL0D3 is a delivery order under SPE2DB20D9331, an indefinite delivery contract.
Was contract SPE2DB26FL0D3 competed?
The extent of competition for SPE2DB26FL0D3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award